New data on Yasmin VTE risk

New evidence suggests that the combined oral contraceptive Yasmin (drospirenone + ethinylestradiol) may be associated with a slightly higher risk of venous thromboembolism (VTE) than previously thought. Although firm conclusions cannot yet be drawn, the likelihood of this rare adverse event in women taking Yasmin is now thought to lie somewhere between that for levonorgestrel-containing pills and that for desogestrel or gestodene-containing pills.

When used appropriately, the benefits of combined oral contraceptives far outweigh the risk of VTE. However, prescribers should consider the new findings during contraceptive consultations and should exercise caution when prescribing Yasmin or any other combined oral contraceptive to women with risk factors for VTE (eg BMI >30kg/m2).

View Yasmin drug record

Further information: MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases